DCF — THEDACARE MED CTR - WILD ROSE
Enterprise Value: $-7.1M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-7.1M
Enterprise Value
$-2.5M
PV of Cash Flows
$-4.5M
PV of Terminal Value
$-7.3M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $13.3M | $-0.3M | -2.0% | $-0.8M | $-0.8M |
| Year 2 | $13.7M | $-0.1M | -1.0% | $-0.7M | $-0.6M |
| Year 3 | $14.1M | $-0.0M | -0.0% | $-0.6M | $-0.5M |
| Year 4 | $14.5M | $0.1M | 0.0% | $-0.6M | $-0.4M |
| Year 5 | $14.9M | $0.1M | 1.0% | $-0.5M | $-0.3M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-7.1M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$12.9M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.025915934626790052
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5